Healthcare technology company Phreesia (NYSE: PHR) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 14.5% year on year to $115.9 million. Its GAAP loss of $0.07 per share increased from -$0.35 in the same quarter last year.

Is now the time to buy PHR? Find out in our full research report (it’s free).

StockStory’s Take

Phreesia’s first quarter saw continued sales growth, though revenue fell short of Wall Street expectations. Management highlighted the impact of products like appointment readiness, post-script engagement, and enhanced bill pay, while attributing year-on-year revenue growth primarily to an increase in average healthcare services clients and higher revenue per client. CEO Chaim Indig highlighted the measurable impact of these offerings on patient and provider outcomes. The company also attributed improved profitability to operating leverage from prior investments in its sales and marketing teams. CFO Balaji Gandhi emphasized that “getting a really good return” on these early investments has been key to Phreesia’s margin improvement, reflecting a more efficient expense structure even as product development remains a priority.

Looking ahead, Phreesia’s guidance is anchored by expectations for continued growth in its network and further margin expansion. Management expects new product modules and increased revenue per client to drive results for the remainder of the year, citing strong early traction from offerings like Medaphine and enhanced bill pay. Gandhi discussed the company's approach to capital allocation, noting a recently approved share repurchase program is an opportunistic tool meant to provide flexibility rather than signal a change in strategy. Indig noted that artificial intelligence is being incorporated across the organization, stating, “AI is enabling us to do things within the Phreesia platform...that we are very excited for.” The company also anticipates ongoing positive free cash flow, though Gandhi cautioned that quarter-to-quarter improvements may vary depending on invoicing and capital expenditures.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to broad-based product adoption, operational discipline, and the early impact of recently launched solutions.

• Product-led growth focus: Phreesia credits growth in patient engagement and bill pay modules for improved outcomes among healthcare clients. Indig highlighted that these solutions have already shown “measurable impact” and are central to the company’s strategy.
• AI integration underway: The company has started embedding artificial intelligence across its operations and product suite, aiming to deliver more scalable, efficient solutions. Indig explained that AI is “allowing us to do things that we weren’t able to do before,” though he noted customers ultimately value practical solutions over the technology itself.
• Network and provider expansion: Client numbers increased over the quarter, with Gandhi noting ongoing strength in both acquiring new customers and expanding business with existing ones. The company’s approach emphasizes landing clients with potential for higher revenue and shorter payback periods.
• Operating leverage from prior investments: Improved margins were attributed to earlier investments in go-to-market functions. Gandhi described the current environment as one where Phreesia is now “getting a really good return” on those investments, leading to greater efficiency.
• Early revenue from new offerings: The Medaphine platform, acquired last year, has begun contributing incremental revenue, though management described its monetization as still very early, characterizing it as “in the first inning.” Enhanced bill pay continues to gain adoption, supporting transaction volume growth across the provider network.

Drivers of Future Performance

Management expects future performance to be driven by continued network growth, increased product adoption, and disciplined cost management.

• Incremental client and product expansion: Phreesia aims to grow its network by adding new healthcare clients and increasing average revenue per client through upselling additional modules and services. Management believes these efforts will support both top-line growth and operating leverage.
• AI-enabled product enhancements: The ongoing rollout of AI-powered features is expected to improve both the efficiency of Phreesia’s solutions and the value delivered to customers. Indig emphasized that AI integration should drive “massive value” for clients and support near-term returns for investors.
• Maintaining operational discipline: Gandhi stated that expense trends are expected to remain relatively flat, with continued focus on maximizing returns from prior investments. Management also anticipates ongoing positive free cash flow, though capital expenditures and working capital timing may cause fluctuations between quarters.

Catalysts in Upcoming Quarters

In the coming quarters, key areas to watch will be (1) the uptake and monetization of new product modules like Medaphine and enhanced bill pay, (2) the pace of AI integration and its ability to drive tangible benefits for clients, and (3) sustained growth in client numbers and average revenue per customer. Execution on disciplined capital allocation, including opportunistic share repurchases, and further operating leverage will also be critical signposts for investors.

Phreesia currently trades at a forward P/E ratio of 25.6×. In the wake of earnings, is it a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.